Pharming Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Pharming Group NV
PHAR Stock  USD 13.23  1.08  8.89%   
Pharming Group's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharming Group's valuation are provided below:
Gross Profit
303.5 M
Profit Margin
(0.02)
Market Capitalization
906.5 M
Enterprise Value Revenue
2.4124
Revenue
339.8 M
There are over one hundred nineteen available trending fundamental ratios for Pharming Group NV, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check out Pharming Group's recent fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 08/10/2025, Market Cap is likely to grow to about 669.4 M. Also, Enterprise Value is likely to grow to about 727.5 M

Pharming Group Total Revenue

312.06 Million

Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.9 M, Interest Expense of 6.6 M or Selling And Marketing Expenses of 6.8 M, as well as many indicators such as Price To Sales Ratio of 2.11, Dividend Yield of 0.0 or PTB Ratio of 3.85. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Build AI portfolio with Pharming Stock
Check out the analysis of Pharming Group Correlation against competitors.

Pharming Group Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets203.6 M400 M213.2 M
Slightly volatile
Short and Long Term Debt Total71.2 M108.4 M73.9 M
Slightly volatile
Other Current Liabilities25.1 M47.7 M27.4 M
Slightly volatile
Total Current Liabilities48.2 M73.8 M49.8 M
Slightly volatile
Property Plant And Equipment Net15.8 M23.3 M16.1 M
Slightly volatile
Accounts Payable10.3 M10.1 M8.7 M
Slightly volatile
Cash71.1 M54.9 M74.5 M
Slightly volatile
Non Current Assets Total76.2 M121.5 M79.3 M
Slightly volatile
Cash And Short Term Investments86.3 M167.9 M92.4 M
Slightly volatile
Net Receivables52.7 M50.2 M17.3 M
Slightly volatile
Common Stock Shares Outstanding46.6 M68.9 M55.4 M
Slightly volatile
Liabilities And Stockholders Equity203.6 M400 M213.2 M
Slightly volatile
Non Current Liabilities Total71.9 M105.1 M73.8 M
Slightly volatile
Inventory58.5 M55.7 M24.4 M
Slightly volatile
Other Current Assets13.6 M13 M4.5 M
Slightly volatile
Other Stockholder Equity402.3 M488.7 M393.5 M
Slightly volatile
Total Liabilities120.1 M178.9 M123.5 M
Slightly volatile
Total Current Assets292.4 M278.4 M144.3 M
Slightly volatile
Short Term Debt6.6 M6.9 M11.3 M
Pretty Stable
Intangible Assets44.3 M61 M44.1 M
Slightly volatile
Common Stock7.4 M7.8 M10.8 M
Slightly volatile
Other Liabilities124.8 K131.4 K18.1 M
Slightly volatile
Capital Lease Obligations17.9 M29.9 M9.6 M
Slightly volatile
Deferred Long Term Liabilities227.4 K239.4 K2.6 M
Slightly volatile
Net Invested Capital268.1 M303.5 M182.2 M
Slightly volatile
Short and Long Term Debt4 M4.2 M17 M
Slightly volatile
Non Current Liabilities Other124.8 K131.4 K17.3 M
Slightly volatile
Net Working Capital145.6 M204.6 M88.3 M
Slightly volatile
Property Plant Equipment47.3 M45 M19.1 M
Slightly volatile
Capital Stock8.2 M7.8 M7.3 M
Slightly volatile
Long Term Investments8.1 M4.2 M6.4 M
Slightly volatile
Property Plant And Equipment Gross47.3 M54.1 M36 M
Slightly volatile

Pharming Group Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense6.6 M8.7 M6.4 M
Slightly volatile
Selling And Marketing Expenses6.8 M7.1 M22 M
Slightly volatile
Total Revenue312.1 M297.2 M125.8 M
Slightly volatile
Other Operating Expenses321.1 M305.8 M117.7 M
Slightly volatile
Research Development87.3 M83.1 M37.6 M
Slightly volatile
Cost Of Revenue37.2 M35.4 M16.1 M
Slightly volatile
Total Operating Expenses283.9 M270.4 M101.6 M
Slightly volatile
Selling General Administrative96.7 M92.1 M27.3 M
Slightly volatile
Interest Income3.1 M4.9 M1.6 M
Slightly volatile
Reconciled Depreciation11.6 M16.1 M7.5 M
Slightly volatile

Pharming Group Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.6 M10.9 M5.7 M
Slightly volatile
Begin Period Cash Flow69 M61.7 M71.8 M
Slightly volatile
Depreciation8.1 M15.5 M6.5 M
Slightly volatile
Capital Expenditures756.2 K796 K5 M
Pretty Stable
End Period Cash Flow71.6 M54.9 M75.3 M
Slightly volatile
Issuance Of Capital Stock4 M2.1 M8.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.112.222157.35
Slightly volatile
Days Sales Outstanding58.5661.6443112
Slightly volatile
Average Payables6.4 M9.3 M7 M
Slightly volatile
Stock Based Compensation To Revenue0.0360.03780.2369
Slightly volatile
Capex To Depreciation0.04670.04921.4127
Slightly volatile
EV To Sales2.292.415254.9308
Slightly volatile
Inventory Turnover0.910.79780.8065
Very volatile
Days Of Inventory On Hand435457701
Pretty Stable
Payables Turnover4.624.40052.5471
Slightly volatile
Sales General And Administrative To Revenue0.30.3211.4606
Slightly volatile
Average Inventory11.8 M21.8 M17.1 M
Slightly volatile
Research And Ddevelopement To Revenue0.240.25572.184
Slightly volatile
Capex To Revenue0.00250.00270.1954
Slightly volatile
Cash Per Share0.220.23520.2888
Slightly volatile
Days Payables Outstanding78.882.9458271
Slightly volatile
Income Quality0.150.15831.1094
Very volatile
Intangibles To Total Assets0.210.15230.1685
Slightly volatile
Current Ratio2.283.64522.7863
Slightly volatile
Receivables Turnover9.745.92118.9086
Very volatile
Capex Per Share0.00110.00110.0144
Slightly volatile
Average Receivables47.8 M45.5 M16.1 M
Slightly volatile
Revenue Per Share0.440.41630.1792
Slightly volatile
Interest Debt Per Share0.160.170.1198
Slightly volatile
Debt To Assets0.220.28020.2703
Slightly volatile
Graham Number0.370.330.298
Slightly volatile
Operating Cycle493519813
Slightly volatile
Days Of Payables Outstanding78.882.9458271
Slightly volatile
Long Term Debt To Capitalization0.460.26050.3724
Slightly volatile
Quick Ratio1.82.91612.2418
Slightly volatile
Net Income Per E B T2.491.35592.7762
Very volatile
Cash Ratio1.30.71861.618
Pretty Stable
Days Of Inventory Outstanding435457701
Pretty Stable
Days Of Sales Outstanding58.5661.6443112
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.44010.9853
Very volatile
Fixed Asset Turnover12.9212.30936.4987
Slightly volatile
Debt Ratio0.220.28020.2703
Slightly volatile
Price Sales Ratio2.112.222157.35
Slightly volatile
Asset Turnover0.780.74150.4464
Slightly volatile

Pharming Group Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap669.4 M637.5 M550 M
Slightly volatile
Enterprise Value727.5 M692.9 M550.8 M
Slightly volatile

Pharming Fundamental Market Drivers

Forward Price Earnings169.4915
Cash And Short Term Investments167.9 M

Pharming Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-64.7 K-61.4 K
Total Revenue297.2 M312.1 M
Cost Of Revenue35.4 M37.2 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.32  0.30 
Research And Ddevelopement To Revenue 0.26  0.24 
Revenue Per Share 0.42  0.44 
Ebit Per Revenue(0.01)(0.01)

Pair Trading with Pharming Group

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharming Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharming Group will appreciate offsetting losses from the drop in the long position's value.

Moving against Pharming Stock

  0.57COV Covalon TechnologiesPairCorr
  0.4IKT Inhibikase TherapeuticsPairCorr
  0.4LPCN LipocinePairCorr
The ability to find closely correlated positions to Pharming Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharming Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharming Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharming Group NV to buy it.
The correlation of Pharming Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharming Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharming Group NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharming Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY